Page last updated: 2024-11-08

pantetheine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pantetheine: An intermediate in the pathway of coenzyme A formation in mammalian liver and some microorganisms. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

pantetheine : An amide obtained by formal condensation of the carboxy group of pantothenic acid and the amino group of cysteamine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID439322
CHEMBL ID1738861
CHEBI ID16753
SCHEMBL ID13599647
MeSH IDM0015821

Synonyms (39)

Synonym
unii-vch6x4iare
vch6x4iare ,
AKOS015841506
CHEBI:16753 ,
(2r)-2,4-dihydroxy-3,3-dimethyl-n-{3-oxo-3-[(2-sulfanylethyl)amino]propyl}butanamide
d-pantetheine
lactobacillus bulgaricus factor
LBF ,
(r)-2,4-dihydroxy-n-(3-((2-mercaptoethyl)amino)-3-oxopropyl)-3,3-dimethylbutyramide
butyramide, 2,4-dihydroxy-n-(2-((2-mercaptoethyl)carbamoyl)ethyl)-3,3-dimethyl-
einecs 207-824-1
butanamide, 2,4-dihydroxy-n-(3-((2-mercaptoethyl)amino)-3-oxopropyl)-3,3-dimethyl-, (r)-
496-65-1
(r)-pantetheine
pantotheine
C00831
pantetheine
(2r)-2,4-dihydroxy-3,3-dimethyl-n-[3-oxo-3-(2-sulfanylethylamino)propyl]butanamide
CHEMBL1738861
d-pantethine hydrate
(r)-2,4-dihydroxy-n-(3-((2-mercaptoethyl)amino)-3- oxopropyl)-3,3-dimethylbutyramide
butanamide, 2,4-dihydroxy-n-(3-((2-mercaptoethyl)amino)-3-oxopropyl)-3,3-dimethyl-, (2r)-
n-(pantothenyl)-.beta.-aminoethanethiol
.alpha.,.gamma.-dihydroxy-.beta.-dimethylbutyryl-.beta.-alanyl-.beta.-aminoethanethiol
pantetheine [mi]
butanamide, 2,4-dihydroxy-n-(3-((2-mercaptoethyl)amino)-3- oxopropyl)-3,3-dimethyl-, (r)-
d-(+)-pantetheine
butyramide, 2,4-dihydroxy-n-(2-((2- mercaptoethyl)carbamoyl)ethyl)-3,3-dimethyl-
SCHEMBL13599647
(r)-2,4-dihydroxy-n-[3-[(2-mercaptoethyl)amino]-3-oxopropyl]-3,3-dimethylbutyramide
(r)-pantetheine, >=95.0% (hplc)
ZNXZGRMVNNHPCA-VIFPVBQESA-N
(r)-2,4-dihydroxy-n-(3-((2-mercaptoethyl)amino)-3-oxopropyl)-3,3-dimethylbutanamide
(2r)-2,4-dihydroxy-n-[3-[(2-mercaptoethyl)amino]-3-oxopropyl]-3,3-dimethylbutanamide
Q192437
CS-0090328
HY-126050
MS-23952
DTXSID50862039

Research Excerpts

Overview

Pantetheine also serves as an amino acid acceptor in reactions catalyzed by AspRS, IleRS, and MetRS.

ExcerptReferenceRelevance
"Pantetheine also serves as an amino acid acceptor in reactions catalyzed by AspRS, IleRS, and MetRS, forming corresponding aminoacyl-S-pantetheine thioesters."( Aminoacylation of coenzyme A and pantetheine by aminoacyl-tRNA synthetases: possible link between noncoded and coded peptide synthesis.
Jakubowski, H, 1998
)
1.3

Toxicity

ExcerptReferenceRelevance
" There was no drug related adverse event during the study."( Pilot trial on the efficacy and safety of pantethine in children with pantothenate kinase-associated neurodegeneration: a single-arm, open-label study.
Chang, X; Jiang, Y; Wang, J; Wu, Y; Yao, B; Zhang, J, 2020
)
0.56

Dosage Studied

ExcerptRelevanceReference
" Both dosage levels depleted IRPRL in pituitary and serum."( Pantethine, a cysteamine precursor, depletes immunoreactive somatostatin and prolactin in the rat.
Bollinger-Gruber, JA; Reichlin, S, 1985
)
0.27
"Pantethine in a dosage of 600 mg for the first 3 months, and in a dosage of 1200 mg for the second 6 months was given to 16 diabetics in whom plasma beta-thromboglobulin was raised (greater than 50 ng/ml)."( Lowering effect of pantethine on plasma beta-thromboglobulin and lipids in diabetes mellitus.
Chonan, N; Eto, M; Ishii, K; Watanabe, K, 1987
)
0.27
" The tolerability of pantethine at the stated dosage and mode of administration was invariably excellent, with non complaints or visible side effects imputable to the test drug."( [Clinical use of pantethine by parenteral route in the treatment of hyperlipidemia].
Arsenio, L; Bodria, P; Bossi, S; Lateana, M; Strata, A, 1987
)
0.27
" 24 months), with oral doses of 600 to 1200 mg of pantethine daily (mean daily dosage 970 mg)."( Pantethine improves the lipid abnormalities of chronic hemodialysis patients: results of a multicenter clinical trial.
Barbi, G; Cairo, G; Degli Esposti, E; Donati, C; Prati, GF, 1986
)
0.27
" Even at high dosage levels, MG 28362 did not cause the characteristic flushing of nicotinic acid congeners."( Pharmacological study of a new hypolipidemic drug of prolonged activity, the tetraester of pantethine with 3-(3-pyridinemethoxycarbonyl)propionic acid.
Gentili, P; Manzardo, S; Riva, M, 1985
)
0.27
"A randomized and double blind experiment has been made over 50 patients and 25 checks, by giving a dosage of 3 Fosfolip (calcium salt of phosphorylcholine chlorid with pantethine) capsules a day."( [Clinical study of the lipotropic activity of the preparation Fosfolip].
Chiti, D; Ligas, B; Proietti, C, 1983
)
0.27
" An effect on bacterial burden was demonstrated in mouse lung and thigh infection models, but further optimization of dosing requirements and compound properties is needed before these compounds can be considered for progress into clinical development."( Discovery of inhibitors of 4'-phosphopantetheine adenylyltransferase (PPAT) to validate PPAT as a target for antibacterial therapy.
Brock, J; Chen, B; de Jonge, BL; Gao, N; Gu, RF; Hajec, L; Holt, E; Hutchings, K; Huynh, H; Johnstone, M; Kutschke, A; Laganas, V; Lahiri, SD; Livchak, S; McKinney, D; Nash, TJ; Neckermann, G; Ni, H; San Martin, M; Thresher, J; Utley, L; Walkup, GK, 2013
)
0.66
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
pantetheines
thiolAn organosulfur compound in which a thiol group, -SH, is attached to a carbon atom of any aliphatic or aromatic moiety.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (6)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of vitamins and cofactors146155
Metabolism of water-soluble vitamins and cofactors102114
Vitamin B5 (pantothenate) metabolism1620
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-20490
1p36 copy number variation syndrome28

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1152960Activity of purified Escherichia coli pantothenate kinase by spectrophotometry2014Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12
Exploring structural motifs necessary for substrate binding in the active site of Escherichia coli pantothenate kinase.
AID1152961Ratio of kcat to Km for purified Escherichia coli pantothenate kinase by spectrophotometry2014Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12
Exploring structural motifs necessary for substrate binding in the active site of Escherichia coli pantothenate kinase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (440)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990203 (46.14)18.7374
1990's61 (13.86)18.2507
2000's77 (17.50)29.6817
2010's77 (17.50)24.3611
2020's22 (5.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.51 (24.57)
Research Supply Index6.18 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index56.46 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials18 (3.87%)5.53%
Reviews20 (4.30%)6.00%
Case Studies3 (0.65%)4.05%
Observational0 (0.00%)0.25%
Other424 (91.18%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]